Breaking News Instant updates and real-time market news.

TSLA

Tesla

$264.29

-43.17 (-14.04%)

, FB

Facebook

$164.44

-4.44 (-2.63%)

19:26
09/30/18
09/30
19:26
09/30/18
19:26

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Securities and Exchange Commission announced that Elon Musk, CEO and Chairman of Tesla (TSLA), has agreed to settle the securities fraud charge brought by the SEC against him last week. The SEC also charged Tesla with failing to have required disclosure controls and procedures relating to Musk's tweets, a charge that Tesla has agreed to settle. According to the settlements, Musk will step down as Tesla's Chairman and be replaced by an independent Chairman, with Musk ineligible to be re-elected Chairman for three years. Meanwhile, Tesla will appoint a total of two new independent directors to its board and will establish a new committee of independent directors and put in place additional controls and procedures to oversee Musk's communications. Further, Musk and Tesla will each pay a separate $20M penalty. 2. A European Union privacy watchdog could fine Facebook (FB) as much as $1.63B for a data breach in which hackers compromised the accounts of more than 50M users, if regulators find the company violated the bloc's strict new privacy law, according to The Wall Street Journal. 3. Potential electoral results could favor the outlook for policies beneficial to a wide range of hospital, pharmaceutical, and other health-care-related companies, Lauren Rublin wrote in this week's edition of Barron's. Policy experts favor Centene (CNC), WellCare Health (WCG), Molina Healthcare (MOH), HCA Healthcare (HCA), Tenet (THC), Encompass Health (EHC), Becton Dickinson (BDX), Cerner (CERN), Dentsply Sirona (XRAY) and Teladoc Health (TDOC) as beneficiaries of Medicaid expansion under the Affordable Care Act, the reported noted, adding that is especially likely if Democrats win more state elections. 4. Comcast (CMCSA) subsidiary Universal's "Night School" debuted to $28M from 3,010 theaters, taking the number one spot of the domestic box office. Overseas, Kevin Hart and Tiffany Haddish's raucous comedy launched to $5.5M from its first 19 markets for $33.5M globally. The movie earned an A- CinemaScore and sports 30% Rotten Tomatoes score. 5. Hasbro (HAS), Royal Dutch Shell (RDS.B, RDS.A), Sanofi (SNY), and IBM (IBM) saw positive mentions in Barron's, while Trupanion's (TRUP) and Tesla were mentioned cautiously.

TSLA

Tesla

$264.29

-43.17 (-14.04%)

FB

Facebook

$164.44

-4.44 (-2.63%)

CNC

Centene

$144.81

1.61 (1.12%)

WCG

WellCare

$320.50

-0.22 (-0.07%)

MOH

Molina Healthcare

$148.73

1.01 (0.68%)

HCA

HCA Healthcare

$139.09

0.75 (0.54%)

THC

Tenet

$28.45

0.1 (0.35%)

EHC

Encompass Health

$78.01

1.33 (1.73%)

BDX

Becton Dickinson

$260.90

1.04 (0.40%)

CERN

Cerner

$64.42

0.21 (0.33%)

XRAY

Dentsply Sirona

$37.74

-0.22 (-0.58%)

TDOC

Teladoc

$86.35

3.85 (4.67%)

CMCSA

Comcast

$35.42

0.19 (0.54%)

CMCSK

Comcast

$0.00

(0.00%)

HAS

Hasbro

$105.12

-0.88 (-0.83%)

RDS.A

Royal Dutch Shell

$68.13

-0.61 (-0.89%)

RDS.B

Royal Dutch Shell

$70.93

-0.37 (-0.52%)

SNY

Sanofi

$44.67

-0.17 (-0.38%)

IBM

IBM

$151.20

-0.3 (-0.20%)

TRUP

Trupanion

$35.73

0.81 (2.32%)

  • 03

    Oct

  • 03

    Oct

  • 09

    Oct

  • 11

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 13

    Nov

  • 11

    Dec

  • 14

    Dec

  • 28

    Jan

  • 03

    Mar

  • 22

    Mar

  • 28

    Apr

TSLA Tesla
$264.29

-43.17 (-14.04%)

09/28/18
09/28/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. CITI CUTS TESLA TO SELL: Citi analyst Itay Michaeli downgraded Tesla (TSLA) to Sell from Neutral and lowered his price target for the shares to $225 from $356. The analyst is making a "risk/reward call" into the outcome of the SEC lawsuit against CEO Elon Musk. In a scenario where the suit leads to Musk's exit, the analyst says there is "little question" that the departure would likely cause harm to Tesla's brand, stakeholder confidence and fundraising. This would increase the risk of triggering a "downward confidence spiral" given the state of Tesla's balance sheet, Michaeli said. Even if Musk were to stay on after settling or prevailing, the analyst believes the "reputational harm" from the suit "might still prevent the stock from immediately returning to 'normal.'" SUNTRUST UPGRADES LOWE'S TO BUY: SunTrust analyst Keith Hughes upgraded Lowe's (LOW) to Buy from Hold and raised his price target to $138 from $110. The analyst cites the company's latest Q2 earnings and the analyst meeting with its management suggesting an "internally focused" turnaround progressing at a "consistent pace" over the next 2-3 years. Hughes adds that even though the stock has recently turned higher, it could rise as much as 50% if the company could reclaim just half of the SG&A difference with Home Depot (HD). STIFEL STARTS ZYNGA WITH A BUY: Stifel analyst Drew Crum initiated Zynga (ZNGA) with a Buy rating and a price target of $5. The analyst cites the "favorable industry for mobile gaming", with annualized mobile gaming revenue expected to increase by 17%. Crum also cites his expectations of greater visibility on its game pipeline and further opportunities to improve adjusted EBITDA. WELLS DOWNGRADES CONTAINERSHIP NAMES: Wells Fargo analyst Michael Webber downgraded the Box Lessor and Containership group saying headwinds from both the International Maritime Organization 2020 fuel regulations and the impact of tariffs have created "significant downside risks" for the stocks. He downgraded Triton International (TRTN), CAI International (CAI) and Costamare (CMRE), all to Market Perform from Outperform, and cut Seaspan (SSW) and Textainer (TGH) to Underperform from Market Perform. He kept a Market Perform rating on Matson (MATX) with an unchanged price target of $35. EVERCORE BOOSTS NVIDIA PRICE TARGET: Evercore ISI analyst C.J. Muse said he believes investors are now more appreciative of Nvidia's (NVDA) opportunity in creating the AI industry standard and the company's "positive feedback loop" within deep learning. Longer-term, he sees tremendous growth opportunities led by the new Turing architecture, which further entrenches Nvidia's high-end gaming moat and presents a "meaningful" opportunity in Inference, Muse said. The analyst, who sees Nvidia being poised to grow EPS at a 30-35% CAGR through 2020 and beyond, raised his price target on the stock to $400 from $300 and kept an Outperform rating on the shares.
09/28/18
RBCM
09/28/18
NO CHANGE
RBCM
Sector Perform
Investors to question whether Musk can remain Tesla CEO, says RBC Capital
RBC Capital analyst Joseph Spak kept his Sector Perform rating on Tesla but noted that the latest civil charges against its CEO Musk will add "more drama" to a volatile stock. The analyst notes that it is difficult to assign a probability on the issue of whether Musk will remain CEO over time since the charges will have to be litigated, but believes that investors will start to consider the depth of the company's bench if he can no longer serve as an officer. Spak further contends that the uncertainty around Tesla's future leadership may weigh on the company's ability to raise additional capital, which it needs to ramp up production of Model 3 sedans over the coming quarters.
09/28/18
SBSH
09/28/18
DOWNGRADE
Target $225
SBSH
Sell
Citi downgrades Tesla to Sell on 'risk of a spiral' from SEC suit
Citi analyst Itay Michaeli downgraded Tesla to Sell from Neutral and lowered his price target for the shares to $225 from $356. The analyst is making a "risk/reward call" into the outcome of the SEC lawsuit against CEO Elon Musk. In a scenario where the suit leads to Musk's exit, the analyst says there is "little question" that the departure would likely cause harm to Tesla's brand, stakeholder confidence and fundraising. This would increase the risk of triggering a "downward confidence spiral" given the state of Tesla's balance sheet, Michaeli tells investors in a research note titled "SEC Action Raises Risk of a Spiral; Risk/Reward Moves Us to Sell." And even if Musk were to stay on after settling or prevailing, the analyst believes the "reputational harm" from the suit "might still prevent the stock from immediately returning to 'normal.'" Even with today's selloff, the stock's risk/reward is still tilted negatively, Michaeli contends.
09/28/18
09/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Sell from Neutral at Citi with analyst Itay Michaeli saying he is making a "risk/reward call" into the outcome of the SEC lawsuit against CEO Elon Musk. 2. IPG Photonics (IPGP) downgraded to Neutral from Buy at Longbow. 3. Phillips 66 Partners (PSXP) downgraded to Underweight at Morgan Stanley with analyst Tom Abrams saying he believes the market is ascribing what he views as relatively high multiples to the units, particularly after recent underperformance by some peers. 4. MedEquities Realty downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Joseph France saying he reduced his expectations for the stock on the assumption that resolving some of its operator issues might take longer than he expected. 5. Apache (APA) and Hess Corp. (HES) were downgraded to Neutral from Overweight at Piper Jaffray. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FB Facebook
$164.44

-4.44 (-2.63%)

09/25/18
BARD
09/25/18
NO CHANGE
Target $195
BARD
Outperform
Facebook survey suggests stabilizing user engagement, says Baird
Baird analyst Colin Sebastian said his latest social media survey suggests stabilizing user engagement on the core Facebook app, following a period of declines. If accurate, the survey suggests concerns over an engagement and monetization-related slowdown may already be reflected in the shares. He also said Q3 estimates embed reasonable expectations for user growth. Sebastian reiterated his Outperform rating and $195 price target on Facebook shares.
09/26/18
BOFA
09/26/18
NO CHANGE
Target $205
BOFA
Buy
BofA/Merrill says Facebook changes may signal accelerated Instagram monetization
Following news that Instagram founders Kevin Systrom and Mike Krieger are leaving Facebook, BofA Merrill Lynch analyst Justin Post said some will express valid concerns that the leadership change is a risk to Instagram culture and usage growth. However, he noted that Facebook purchased Instagram over five years ago and does not anticipate a near-term financial impact. He also thinks acceleration of Instagram monetization is possible and believes investors may reconsider the potential value in Messenger and WhatsApp. Post maintains a Buy rating and $205 price target on Facebook shares.
09/25/18
RHCO
09/25/18
NO CHANGE
Target $200
RHCO
Buy
Instagram 'in a good place' after Systrom, Krieger resignations, says SunTrust
SunTrust analyst Youssef Squali maintained a Buy rating and $200 price target on Facebook following the departure of Instagram co-founders Kevin Systrom and Mike Krieger. In a research note to investors, the analyst notes that the departures are the "latest in a string" of high profile departures in recent months, including WhatsApp co-founders Jan Koum and Brian Acton and VP and General Counsel Colin Stretch, and follows a restructuring earlier this year that reorganized the entire company. Squali contends that Instagram is "in a good place" and is being left with "stable footing," as well as "impressive" growth in users as Stories DAUs, adding that product cadence has slowed and it is entering a new phase of its life. Squali feels a deeper integration with Facebook could lead to an improved advertising product and monetization, which Systrom and Krieger may have been more resistant to, and does not see any material changes at the Facebook unit in the near-term.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
JPMorgan sees 'meaningful pressure' on Facebook shares from Instagram departures
JPMorgan analyst Doug Anmuth says the "surprising" departure of Instagram co-founders Kevin Systrom and Mike Krieger is concerning and likely to put "meaningful pressure" on shares of Facebook (FB) in the near-term. The analyst believes Instagram has been a strong growth driver for Facebook and has played a critical role in retaining younger users within the company's group of platforms and in competing with Snap (SNAP). While the exact rationale for the co-founders' departure is unclear, various press reports suggest it is related to Facebook management recently exerting more control over Instagram, Anmuth tells investors in a research note. The analyst has an Overweight rating on Facebook. The stock in premarket trading is down 2%, or $3.71, to $161.70.
CNC Centene
$144.81

1.61 (1.12%)

09/04/18
FBCO
09/04/18
NO CHANGE
Target $152
FBCO
Neutral
Centene price target raised to $152 from $134 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Centene to $152 from $134 after surveying 737 health benefit managers across the country to gain insight into market perceptions regarding national health insurers, cost trends, premium expectations, and employer priorities heading into 2019. The analyst notes that the survey bodes well for his MCOs coverage. He reiterates a Neutral rating on the shares.
07/25/18
FBCO
07/25/18
NO CHANGE
Target $134
FBCO
Neutral
Centene price target raised to $134 from $125 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Centene to $134 from $125, while reiterating a Neutral rating on the shares. The analyst believes there was more noise than expected for a Q2 on the heels of an Investor Day.
09/28/18
OPCO
09/28/18
NO CHANGE
Target $89
OPCO
Outperform
Teladoc price target raised to $89 from $68 at Oppenheimer
Oppenheimer analyst Mohan Naidu reiterated an Outperform rating on Teledoc and raised his price target to $89 from $68 following the company's analyst day, which highlighted its new deal flow, including relationships with Centene (CNC) and Exxon (XOM), and a very strong pipeline. The recent CMS telehealth proposal makes Medicare a 2020 tailwind, Naidu tells investors in a research note, and says he has gained confidence that Teladoc's competitive barriers include its broad platform and its network of physicians that quickly matches supply and demand.
09/19/18
MUFG
09/19/18
INITIATION
Target $170
MUFG
Overweight
Centene initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started Centene with an Overweight rating and $170 price target. The analyst sees an attractive risk/reward profile given the stock's discount to peers. He believes Centene's "significant" Medicaid and Medicare growth opportunities make the discount unwarranted.
WCG WellCare
$320.50

-0.22 (-0.07%)

08/31/18
ARGS
08/31/18
NO CHANGE
Target $360
ARGS
Buy
WellCare price target raised to $360 from $265 at Argus
Argus analyst David Toung raised his price target on WellCare to $360 and kept his Buy rating, saying the company's acquisition of Meridian is a reflection of its "expansion mode". The analyst also raised his FY19 EPS view to $12.60 from $12.00, stating that WellCare's growth opportunities from its M&A strategy justifies its premium valuation of 24.1-times his expected forward earnings - above the peer average of 19.0-times. Toung maintains that WellCare will continue to grow through acquisitions, increased Medicare Advantage coverage, and new contract awards.
08/01/18
RHCO
08/01/18
NO CHANGE
Target $315
RHCO
Buy
WellCare price target raised to $315 from $295 at SunTrust
SunTrust analyst David MacDonald raised his price target on WellCare to $315 and kept his Buy rating, saying the company's Q2 earnings beat was driven by "strong core trends". The analyst also cites "superb" visibility around the company's "impressive" win rates and its large number of members in states with leading market share. MacDonald adds that Wellcare's Medicare Advantage trends are solid, and that the company is "superbly positioned" to accelerate trends in 2019.
09/14/18
BMOC
09/14/18
NO CHANGE
Target $345
BMOC
Outperform
WellCare price target raised to $345 from $320 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on WellCare to $345 to reflect the potential organic upside for FY18 EPS as well as the accretion from its Meridian acquisition in FY19-FY20. The analyst maintains his view of the deal as a "very good strategic fit" to match WellCare's expansion objectives, adding that its recent Medicaid wins in Illinois and Michigan also gives WellCare a leading market position in 6 states. Borsch kept his his Outperform rating on the shares, forecasting its core business growth rate to be sustained at over 15%.
09/17/18
CANT
09/17/18
NO CHANGE
Target $330
CANT
Overweight
WellCare price target raised to $330 from $292 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for WellCare Health Plans to $330 after incorporating the recently closed acquisition of Meridian into his 2018 estimates. The analyst now assumes high single-digit revenue growth and thinks the company's margin expansion "is quite achievable" for the near-to-mid-term. He keeps an Overweight rating on WellCare.
MOH Molina Healthcare
$148.73

1.01 (0.68%)

08/02/18
RHCO
08/02/18
NO CHANGE
Target $140
RHCO
Buy
Molina Healthcare price target raised to $140 from $120 at SunTrust
SunTrust analyst David MacDonald raised his price target on Molina Healthcare to $140 and kept his Buy rating after its "blowout" Q2 results driven by "stronger premium revenue, sequential MCR improvement, solid G&A expense control, and marketplace outperformance." The analyst also cites the company's improving capital structure and "meaningful" margin expansion, raising his FY18 EPS view to $7.52 from $4.58.
08/02/18
PIPR
08/02/18
NO CHANGE
Target $134
PIPR
Overweight
Molina Healthcare price target raised to $134 from $106 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $134 saying the company's turnaround is running ahead of schedule. Management could raise 2019 guidance at the next investor day driven by faster margin recovery and potentially capital deployment, James tells investors in a research note following Molina's Q2 results. The analyst reiterates an Overweight rating on the shares.
08/02/18
WELS
08/02/18
NO CHANGE
Target $120
WELS
Market Perform
Molina Healthcare price target raised to $120 from $92 at Wells Fargo
Wells Fargo raised its price target for Molina Healthcare to $120 from $92 after the company reported a notably better than expected Q2 driving an improved outlook. The firm reiterates a Market Perform rating on the shares.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $165
PIPR
Overweight
Molina Healthcare price target raised to $165 from $134 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $165 and keeps an Overweight rating on the shares. Puerto Rico finalized the auto assignment process for the $2.2B contract starting November 1, and while Molina is is not confirming the impact, the analyst believes it could be a $150M revenue headwind for the company. Nonetheless, James feels confident in the company's Q3 results. She believes much of the turnaround success demonstrated in Q2 "will continue to have lasting impacts such as network design and contracting and admin. efficiency."
HCA HCA Healthcare
$139.09

0.75 (0.54%)

09/06/18
ARGS
09/06/18
NO CHANGE
Target $150
ARGS
Buy
HCA Healthcare price target raised to $150 from $116 at Argus
Argus analyst Jasper Hellweg raised his price target on HCA Healthcare to $150 and kept his Buy rating, saying the company's recent acquisition of Mission Heath in North Carolina strengthens its regional presence. The analyst also cites the managements expectations of healthcare services demand rising 2.0-2.5% annually on "population growth, strong economic conditions, higher medical utilization, and an increase in the number of patients with chronic conditions." Hellweg raises his FY18 EPS view on HCA Healthcare to $9.24 from $8.74, adding that its valuation is "attractive" at 14.4-times expected FY18 earnings vs. 17.5-times peer group average.
09/20/18
BARD
09/20/18
NO CHANGE
Target $150
BARD
Outperform
HCA Healthcare price target raised to $150 from $130 at Baird
Baird analyst Matthew Gillmor raised his price target on HCA Healthcare to $150 from $130 to reflect positive management commentary at an investor conference and the pending Mission Health acquisition. Gillmor reiterated his Outperform rating and called HCA Healthcare his preferred hospital idea.
09/10/18
RBCM
09/10/18
NO CHANGE
Target $150
RBCM
Outperform
HCA Healthcare price target raised to $150 from $130 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on HCA Healthcare to $150 and kept his Outperform rating, citing the financial contribution from "several pending transitions" that are yet to close. The analyst highlights the $1.5B deal to acquire Mission Health in North Carolina and North Cypress in Houston, stating that these will add to the company's anticipated tailwinds in 2019. Morgan is also positive on the "improved performance" from HCA Heathcare's other Houston-area hospitals that were acquired from Tenet last year.
09/20/18
JEFF
09/20/18
NO CHANGE
Target $155
JEFF
Buy
HCA Healthcare price target raised to $155 from $135 at Jefferies
Jefferies analyst Brian Tanquilut raised his price target for HCA Healthcare to $155 saying the stock "still has room to run" despite the year-to-date rally. HCA is well positioned to deliver organic revenue and EBITDA growth acceleration in the next few years, as it benefits from economic/population growth in its markets, strategic investments and selective acquisitions, Tanquilut tells investors in a research note. Further, the analyst believes "easy" Q3 comps and the tailwind from an upcoming Medicare rate bump "should provide incremental stock momentum." He keeps a Buy rating on the shares.
THC Tenet
$28.45

0.1 (0.35%)

08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
08/14/18
LEHM
08/14/18
INITIATION
Target $35
LEHM
Equal Weight
Tenet initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Tenet Healthcare with an Equal Weight rating and $35 price target.
08/08/18
MZHO
08/08/18
NO CHANGE
Target $36
MZHO
Buy
Tenet post-earnings selloff seems overdone, says Mizuho
Mizuho analyst Ann Hynes believes the post-earnings selloff yesterday in shares of Tenet Healthcare seems overdone. The Q2 earnings report shows Tenet has initiatives underway that should improve its earnings, margin and cash flow profile, Hynes tells investors in a research note. The analyst raised her price target for the shares to $36 from $35 and keeps a Buy rating on Tenet.
07/23/18
SBSH
07/23/18
NO CHANGE
Target $44
SBSH
Buy
Tenet price target raised to $44 from $37 at Citi
Citi analyst Ralph Giacobbe raised his price target for Tenet Healthcare to $44 saying he sees additional upside in the stock despite the 140% rally year-to-date. There is an underappreciation for additional upside within the hospital segment specifically around margin improvement, Giacobbe tells investors in a research note partially titled "Debunking the Rationale for Lower Margins." He keeps a Buy rating on Tenet.
EHC Encompass Health
$78.01

1.33 (1.73%)

07/26/18
07/26/18
UPGRADE
Target $87

Overweight
Encompass Health upgraded to Overweight on top-line growth potential at Piper Jaffray
As previously reported, Piper Jaffray analyst Sarah James upgraded Encompass Health to Overweight from Neutral and raised her price target on the stock to $87 from $68 following her deep dive into top-line growth opportunities and rate risk. Noting that Encompass Health is her top pick within the facility space, the analyst says its strong balance sheet gives it the opportunity to meaningfully move top-line growth through M&A. Further, James sees potential for the HH segment to increase 43% through strategically placed assets and higher collaboration rates.
07/26/18
PIPR
07/26/18
UPGRADE
PIPR
Overweight
Encompass Health upgraded to Overweight from Neutral at Piper Jaffray
04/30/18
CHLM
04/30/18
NO CHANGE
Target $71
CHLM
Buy
Encompass Health price target raised to $71 from $63 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Encompass Health to $71 from $63 following a Q1 beat and raise. The analyst reiterates a Buy rating on the shares.
04/30/18
RBCM
04/30/18
NO CHANGE
Target $69
RBCM
Outperform
Encompass Health price target raised to $69 from $64 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on Encompass Health to $69, saying the company's Q1 marked "another strong quarter with continued topline growth on impressive organic volumes". Morgan also notes that the company's operating leverage is "impressive" while its labor management is "effective", adding that Encompass Health is off to a great start on its rebranding efforts. The analyst keeps his Outperform rating.
BDX Becton Dickinson
$260.90

1.04 (0.40%)

09/06/18
WELS
09/06/18
NO CHANGE
Target $290
WELS
Outperform
Becton Dickinson price target raised to $290 form $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Becton Dickinson to $290 from $275 based on a blend of P/E and EV/EBITDA multiples to reflect increased peer group valuation. After hosting the company's management, the analyst believes that it has a good line of sight into key businesses and is confident in delivering 7% top-line growth in Q4. Biegelsen reiterates an Outperform rating on the shares.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
06/21/18
JPMS
06/21/18
UPGRADE
Target $275
JPMS
Overweight
Becton Dickinson upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Robbie Marcus upgraded Becton Dickinson to Overweight and raised his price target for the shares to $275 from $250. The analyst sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. With sustainable 5% organic sales growth, a minimum of low-double-digit earnings growth "arguably a given for the foreseeable future," and sustainable 90% free cash flow conversion, Becton deserves a premium multiple even after factoring in its leverage, Marcus tells investors in a research note.
06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CERN Cerner
$64.42

0.21 (0.33%)

09/13/18
LEHM
09/13/18
INITIATION
Target $370
LEHM
Overweight
Barclays sees favorable Medicare Advantage outlook, starts Humana at Overweight
Barclays analyst Steve Valiquette initiated coverage of Humana (HUM) with an Overweight rating and $370 price target. The fundamental Medicare Advantage outlook is the strongest it has been since pre-Affordable Care Act levels "thanks to a number of industry tailwinds brought about by the Republican administration," Valiquette tells investors in a research note. These include higher Medicare reimbursement, corporate tax reform, and 2019 health insurance fund suspension, the analyst says. He believes Humana will be able to deliver on its low-to-mid-teens annual adjusted earnings target through at least 2021. Valiquette this morning also initiated coverage of Cerner with an Equal Weight rating and $70 price target. The company's 7%-12% revenue growth outlook relies on the ramp-up of newer products, the analyst contends.
08/13/18
OPCO
08/13/18
NO CHANGE
OPCO
CMS guidelines 'a strong tailwind' for Evolent Health, says Oppenheimer
Oppenheimer analyst Mohan Naidu notes that CMS's new risk-based model rules confirm his expectation of a much more expedited and aggressive move to push providers toward higher double-sided risk models. The draft lays a path for ACOs to 2-sided profit/loss-sharing models starting with 25% profit-only sharing to 75% profit/loss-sharing, he adds. The analyst believes these rules will force providers to seek solutions and services that help organizations manage risk and perform better in risk contracts. Naidu thinks the biggest beneficiary of these movements is Evolent Health (EVH), and given Cerner's (CERN) recent investment into Lumeris and their position in hospitals, it is likely to benefit as well. Also, the draft highlights the use of telehealth and medication therapy management, further validating his bullishness on Teladoc (TDOC) and Tabula Rasa HealthCare (TRHC).
08/16/18
CANT
08/16/18
NO CHANGE
CANT
Overweight
Cantor Fitzgerald backs 'positive' view of healthcare IT segment
Cantor Fitzgerald Steven Halper tells investors in a research note that he is maintaining a positive investment view of the healthcare IT segment, and believes demand for products and services in the sector will continue to drive long-term growth. Specifically, he continues to rate Cerner (CERN) and Evolent Health (EVH) Overweight, as both are "nicely" leveraged to population health, with Evolent mostly a pure play in the segment. Within managed care, Halper believes Overweight-rated UnitedHealth (UNH) remains well-positioned with its Optum segment.
09/13/18
LEHM
09/13/18
INITIATION
Target $70
LEHM
Equal Weight
Cerner initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Cerner with an Equal Weight rating and $70 price target.
XRAY Dentsply Sirona
$37.74

-0.22 (-0.58%)

08/08/18
08/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Aramark (ARMK) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying the shares rallied following its results, which helped balance the risk/reward. 2. Hostess Brands (TWNK) downgraded to Sector Perform from Outperform at RBC Capital and to Hold from Buy at SunTrust. 3. Spark Therapeutics (ONCE) downgraded to Market Perform from Outperform at BMO Capital with analyst Matthew Luchini saying he believes that the company's latest SPK-8011 hemA data falls short of expectations, with totality of the data suggesting a "less competitive profile versus valrox" and reducing his confidence in the program. 4. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at Raymond James with analyst Elliot WIlbur saying pipeline optionality remains high and is heavily discounted by valuation, and sees no "rational valuation framework" to support further upside. 5. Dentsply Sirona (XRAY) downgraded to Equal Weight from Overweight at Stephens and to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/09/18
BRRR
08/09/18
DOWNGRADE
BRRR
Market Perform
Dentsply Sirona downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Dentsply Sirona to Market Perform saying the company's reduced 2018 guidance is "highly disappointing." The analyst sees "massive uncertainty" surrounding the company's business beyond this year.
08/09/18
BRRR
08/09/18
DOWNGRADE
BRRR
Market Perform
Dentsply Sirona downgraded to Market Perform from Outperform at Barrington
08/31/18
HCWC
08/31/18
NO CHANGE
Target $40
HCWC
Neutral
Dentsply Sirona may lower earnings guidance further, says H.C. Wainwright
Lower dental segment operating margins at Patterson Companies (PDCO) may hinder earnings growth at Dentsply Sirona (XRAY), H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. Patterson's dental segment in its fiscal Q1 results showed an internal sales decline of 2.7% year-over-year, following a decline of 10.5% in the previous quarter, Selvaraju points out. The analyst would not be surprised if Dentsply lowers its earnings guidance further in the coming quarter. He reiterates a Neutral rating on the shares with a $40 price target.
TDOC Teladoc
$86.35

3.85 (4.67%)

09/28/18
ADAM
09/28/18
NO CHANGE
Target $94
ADAM
Buy
Teladoc price target raised to $94 from $86 at Canaccord
Canaccord analyst Richard Close raised his price target on Teladoc to $94 from $86 following its "impressive" investor day. The analyst noted the company raised its guidance and shed some light on the international opportunity. He believes the company has strong sustainable momentum with global opportunities and is just beginning to scratch the surface. Close reiterated his Buy rating on Teladoc shares.
09/28/18
SBSH
09/28/18
NO CHANGE
Target $95
SBSH
Buy
Teladoc price target raised to $95 from $88 at Citi
Citi analyst Stephanie Demko raised her price target for Teladoc to $95 after the company held its second annual investor day yesterday. Management's tone was positive on the macro environment, new wins and momentum as the business gains scale, Demko tells investors in a research note. She left the meeting "incrementally more positive" on the company's growth sustainability through 2020 and beyond. The analyst reiterates a Buy rating on Teladoc.
09/28/18
CANT
09/28/18
NO CHANGE
Target $83
CANT
Neutral
Teladoc price target raised to $83 from $52 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Teladoc to $83 saying the company at its investor meeting provided a bullish overview of its long-term growth potential. The analyst, however, reiterates a Neutral rating on the shares. He believes the stock at current valuation levels reflects his revised long-term growth assumptions.
CMCSA Comcast
$35.42

0.19 (0.54%)

09/24/18
09/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pinnacle Foods (PF) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery citing the expectation that the announced deal with ConAgra (CAG) will be approved. 2. Comcast (CMCSA) downgraded to Neutral from Buy at MoffettNathanson and to Perform from Outperform at Oppenheimer. 3. K2M Group (KTWO) downgraded to Sector Perform from Outperform at RBC Capital with analyst Glenn Novarro following its agreement to be acquired by Stryker (SYK). 4. Bloomin' Brands (BLMN) downgraded to Market Perform from Outperform at BMO Capital with analyst Andrew Strelzik saying the sector's comps should start decelerating in Q4 as commodity deflation widens the gap between "food- at-home/food-away-from-home price," adding that the comps at Outback have historically the strongest relationship with changes in commodity prices. 5. Nutanix (NTNX) downgraded to Negative from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/18
KEYB
09/26/18
NO CHANGE
Target $43
KEYB
Overweight
Comcast price target raised to $43 from $38 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for Comcast ((CMCSA) to $43 from $38 as he sees a positive risk/reward. The analyst expects Comcast's cable business to outperform expectations, which should drive improved sentiment and profitability over the next one to two years. Nispel also believes there is an overhang lifted on the stock following its Sky (SKYAY) auction win. Comcast's management acumen to integrate Sky and the strategic value of the assets are underappreciated by Comcast investors, he contends, reiterating an Overweight rating on the shares.
09/25/18
JEFF
09/25/18
DOWNGRADE
JEFF
Hold
Sky downgraded to Hold from Buy at Jefferies
Jefferies analyst Jerry Dellis downgraded Sky (SKYAY) to Hold and lowered his price target for the shares to 1,728p from 1,750p. The analyst fully expects Comcast's offer to be accepted, allowing the acquisition to close by end-October.
09/24/18
BERN
09/24/18
NO CHANGE
BERN
Sky's bidding war outcome 'best possible result' for Disney, says Bernstein
Bernstein analyst Todd Juenger says this weekend's outcome of the bidding war for Sky (SKYAY) was "the best possible result" for Disney (DIS). The analyst argues that he never understood why Disney would want to operate a European DBS business, and never understood how Sky would contribute to Disney's DTC strategy. Rather than pay such a premium like Comcast (CMCSA), Disney can now get "paid" that premium, assuming Fox (FOXA) agrees to sell and deliver the proceeds to Disney in lieu of the shares they had promised, the analyst contends.
CMCSK Comcast
$0.00

(0.00%)

07/13/18
BERN
07/13/18
NO CHANGE
BERN
Bernstein 'not so sure' Comcast will give up on Fox assets
Bernstein analyst Todd Juenger said that it appears that the market is starting to believe Comcast (CMCSA) will give up on its bid to buy assets from 21st Century Fox (FOXA) and focus on Sky (SKYAY), but he said he is "not so sure" that is the case after only one counter from Disney (DIS). He does not believe Comcast would put forth a $35 bid unless it was prepared to bid up to near $45 per share, Juenger tells investors. If Comcast ups its bid, it either wins Fox at a high price or Disney is forced to pay more, which both seem better than giving up to him, Juenger stated. In any case, the "winner" will be left with increased leverage on a cyclical business late in the cycle at a time when it needs to invest significantly to build its direct-to-consumer business, added Juenger.
07/13/18
07/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. VF CORP DOUBLE UPGRADE: BofA Merrill Lynch analyst Robert Ohmes upgraded VF Corp (VFC) to Buy from Underperform and raised his price objective to $96 from $65 ahead of the company's earnings report on July 20, telling investors in a research note that he believes Vans will be a "go-to-brand" for the back-to-school selling season. He said his channel checks indicate accelerating momentum in Vans, especially classic styles, and that the $50-$60 price point is attractive given consumers' shift to value. RAYMOND JAMES DOWNGRADES AT&T: Raymond James downgraded AT&T (T) to Market Perform from Outperform. Analyst Frank Louthan said he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. AT&T is lower by 2% in late morning trading. STIFEL STARTS GALMED WITH A BUY: Stifel analyst Adam Walsh initiated Galmed (GLMD) with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH. Galmed is trading higher by over 17% in late morning trading. MORGAN STANLEY HIKES WWE TARGET TO $100: Morgan Stanley analyst Benjamin Swinburne said that WWE (WWE), by securing rights fees in its new five-year agreements with NBC (CMCSA, CMCSK) and Fox (FOX, FOXA) that are 3.6 times higher than its prior five-year broadcast agreement with NBC, has gained a "massive increase" in earnings power and "extremely high" visibility into the associated revenue. Given the recently announced deals, he raised his price target on WWE shares to $100 from $58 and kept an Overweight rating on the stock. WILLIAM BLAIR CALLS KEMPER PULLBACK 'BUYING OPPORTUNITY': William Blair analyst Adam Klauber said he views shares of Kemper (KMPR) as "even more attractive" after the recent pullback, which he attributes to selling pressures from Infinity Property shareholders receiving Kemper stock. Klauber said Kemper "continues to be our top conviction idea," and kept an Outpeform rating on the name. Kemper is higher by 4.8% in late morning trading.
07/25/18
JPMS
07/25/18
NO CHANGE
JPMS
Overweight
Invalidated patent 'not material' to TiVo court fight, says JPMorgan
JPMorgan analyst Sterling Auty noted that the USPTO's Patent Trial and Appeal Board has declared patent 8,433,696 held by TiVo (TIVO) to be invalid as it believes that the technology involves a variation of earlier know-how. While a "scary headline," the reality is this does not matter in terms of TiVo's court case with Comcast (CMCSA), since this patent was dropped from the case, said Auty, who keeps an Overweight rating on TiVo shares.
HAS Hasbro
$105.12

-0.88 (-0.83%)

08/15/18
MKMP
08/15/18
UPGRADE
Target $115
MKMP
Buy
Hasbro upgraded to Buy at MKM Partners on expected 'material recovery'
As reported earlier, MKM Partners analyst Eric Handler upgraded Hasbro (HAS) to Buy from Neutral and raised his price target to $115 from $92. The analyst says investors should look beyond the 2018 industry issues and anticipate a "material fundamental recovery" in the next two years thanks to the company's large toy line additions and expected margin expansion. Handler models a double-digit earnings growth to reach $6 EPS by 2020, which he says still does not include the anticipated PLAYSCHOOL partnership with Netflix (NFLX) or feature film investment benefits.
08/15/18
08/15/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NVIDIA DOUBLE UPGRADE AHEAD OF EARNINGS: Wells Fargo analyst Aaron Rakers upgraded Nvidia (NVDA) two notches to Outperform from Underperform and raised his price target to $315 from $140, citing the company's competitive position in gaming as well as its AI / deep learning data center growth opportunities. Rakers also points to the company's new Turing GPU architecture as well as the "well-understood" investor perception of weakening in cryptocurrency-related demand. MKM SAYS LOOK BEYOND NEAR-TERM, BUY HASBRO: MKM Partners analyst Eric Handler upgraded Hasbro (HAS) to Buy from Neutral and raised his price target to $115 from $92 as he contends investors should look beyond the 2018 industry issues and anticipate a "material fundamental recovery" in the next two years thanks to the company's large toy line additions and expected margin expansion. WESTERN DIGITAL CUT TO PERFORM: Cowen analyst Karl Ackerman downgraded Western Digital (WDC) to Market Perform from Outperform as his recent supply chain field work pointed to "substantial, unabated competitive pricing tactics" by the company and Toshiba (TOSBF) to gain share of enterprise and client solid state drives. He also worries that Western Digital's efforts to scale back incremental NAND wafer adds to support pricing is not without significant risk. STIFEL SAYS BUY GW PHARMA AHEAD OF EPIDIOLEX LAUNCH: Stifel analyst Paul Matteis started GW Pharmaceuticals with a Buy rating and $181 price target, as he expects a "strong" Epidiolex launch in Dravet/Lennox Gastaut and put an 80% odds-of-success for Epidiolex in Tuberous Sclerosis complex. The analyst's epilepsy physician survey suggests broad physician and patient awareness of Epidiolex ahead of the launch, believes the 2019 consensus sales estimate of $115M "seems doable" and forecasts Epidiolex will hit $1.5B in U.S. sales in 2023.
09/14/18
JEFF
09/14/18
NO CHANGE
Target $120
JEFF
Buy
Jefferies sees 50% upside in Hasbro, adds to Franchise Picks List
Jefferies analyst Stephanie Wissink added Hasbro to her firm's Franchise Picks List saying she sees 50% stock appreciation potential over the next one-to-two years. Hasbro's toy sales stand to grow and generate "strong" cash flow, backed by the company's "superior brand and content pipeline," Wissink tells investors in a research note. Further, she adds the company's direct strategies in media and gaming "are layered atop two powerful profit streams that carry higher multiples." The analyst keeps a Buy rating on the shares.
08/15/18
08/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nvidia (NVDA) double-upgraded two notches to Outperform from Underperform at Wells Fargo with analyst Aaron Rakers citing the company's long-term prospects given its competitive position in gaming as well as its AI / deep learning data center growth opportunities. 2. Hasbro (HAS) upgraded to Buy from Neutral at MKM Partners with analyst Eric Handler saying investors should look beyond the 2018 industry issues and anticipate a "material fundamental recovery" in the next two years thanks to the company's large toy line additions and expected margin expansion. 3. Incyte (INCY) upgraded to Outperform from Sector Perform at RBC Capital with analyst Brian Abrahams citing the company's "unique situation" position as a "revenue-generating, high-opex, broad-pipeline mid-cap, which should enable it to pull multiple levers" to unlock value and produce shareholder interest. 4. Norfolk Southern (NSC) upgraded to Buy from Hold at Deutsche Bank reflecting increased conviction that out-year earnings power is underappreciated. 5. Papa John's (PZZA) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying he believes near-term expectations have been reset to a reasonable level following the company's disappointing Q2 results and report of "lackluster" same-store sales in Q3 to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RDS.A Royal Dutch Shell
$68.13

-0.61 (-0.89%)

09/28/18
STFL
09/28/18
NO CHANGE
Target $5
STFL
Buy
Stifel reiterates Buy on Civeo as Shell seems close to starting LNG project
Noting that several reports over the last few days indicate a positive decision about a Shell-led (RDS.A) LNG project in Western Canada could be announced as soon as next week, Stifel analyst Stephen Gengaro reiterated his Buy rating and $5 price target on shares of Civeo (CVEO), for whom he has previously said the Shell project could be a "game-changer." If the LNG project receives a positive final investment decision, he believes Civeo will benefit via its ownership of Sitka Lodge, its 40% owned joint venture with Bird Construction and the potential for a long-term project for Civeo to provide ancillary services, said Gengaro.
09/11/18
BREN
09/11/18
INITIATION
BREN
Hold
Royal Dutch Shell initiated with a Hold at Berenberg
Berenberg analyst Henry Tarr started Royal Dutch Shell with a Hold rating and EUR 31 price target.
08/31/18
08/31/18
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. BP (BP) and Royal Dutch Shell (RDS.A) were upgraded to Hold from Underperform at Santander. 2. Dollar Tree (DLTR) downgraded to Market Perform from Outperform at Telsey Advisory. 3. Electronic Arts (EA) and Activision Blizzard (ATVI) were downgraded to Neutral from Buy at BofA/Merrill. 4. Gain Capital (GCAP) initiated with a Neutral at JPMorgan. 5. Avaya (AVYA) initiated with a Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/31/18
SANT
08/31/18
UPGRADE
SANT
Hold
Royal Dutch Shell upgraded to Hold from Underperform at Santander
RDS.B Royal Dutch Shell
$70.93

-0.37 (-0.52%)

11/03/17
SOCG
11/03/17
DOWNGRADE
SOCG
Hold
Royal Dutch Shell downgraded to Hold from Buy at Societe Generale
Societe Generale downgraded Royal Dutch Shell to Hold citing valuation.
SNY Sanofi
$44.67

-0.17 (-0.38%)

09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
IBM IBM
$151.20

-0.3 (-0.20%)

09/26/18
UBSW
09/26/18
UPGRADE
Target $180
UBSW
Buy
IBM upgraded to Buy from Neutral at UBS
UBS analyst John Roy upgraded IBM to Buy and raised his price target for the shares to $180 from $160. The market is pricing in a 2% revenue decline, which IBM can beat, Roy tells investors in a research note. Further, his sum-of-the-parts analysis suggests the market is applying virtually no value to IBM's hardware business, which the analyst thinks is "unrealistic." Roy sees a number of additional positives, including operating margin improvement, the Watson hype cycle bottoming this year, and a 4.4% dividend "providing a floor."
09/26/18
09/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. UBS UPGRADES IBM TO BUY: UBS analyst John Roy upgraded IBM (IBM) to Buy and raised his price target for the shares to $180 from $160. The market is pricing in a 2% revenue decline, which IBM can beat, Roy believes. Further, his sum-of-the-parts analysis suggests the market is applying virtually no value to IBM's hardware business, which the analyst thinks is "unrealistic." Roy sees a number of additional positives, including operating margin improvement, the Watson hype cycle bottoming this year, and a 4.4% dividend "providing a floor." Shares of IBM were higher by 2% in late morning trading. OPPENHEIMER UPGRADES GOPRO TO OUTPERFORM: Oppenheimer analyst Andrew Uerkwitz upgraded GoPro (GPRO) to Outperform from Perform, with a $9 price target. The analyst believes the company has done everything it can to position itself for success. With compelling features such as live streaming and gimbal-like image stabilization, Uerkwitz called its products are "compelling." This should be enhanced by targeted marketing and a vastly improved software editing suite, he contended. In late morning trading, GoPro shares were higher by 4%. PIPER JAFFRAY BOOSTS ACTIVISION BLIZZARD PRICE TARGET: Piper Jaffray analyst Michael Olson raised his price target for Activision Blizzard (ATVI) to $88 from $84 saying he's increasingly confident in potential for earnings upside in 2018 from "Call of Duty Black Ops 4" and the accompanying Blackout battle royale mode. Both gamer and critical feedback on Blackout have been favorable, Olson said. He believes the Street has underestimated the potential for collective Call of Duty franchise revenue in 2018 and into 2019 and maintained an Overweight rating on shares. UBS CUTS LAM RESEARCH TO NEUTRAL: UBS analyst Tim Arcuri downgraded Lam Research (LRCX) to Neutral from Buy and lowered his price target for the shares to $170 from $220. Arcuri is "stepping to the sidelines" because he sees a big risk for the company in the first half of 2019 due to Lam Research's outsized exposure to Samsung. In late morning trading, shares of Lam Research were lower by almost 2%. DA DAVIDSON STARTS LULULEMON WITH A NEUTRAL: DA Davidson analyst John Morris initiated Lululemon (LULU) with a Neutral rating and a price target of $155, saying the "quality of its long-term growth rate is not as robust as it has been" even though its forward earnings multiple is near historical highs. The analyst noted that the company's "future growth has higher risk variables associated with the complexity of international expansion across multiple continents and fashion cycle headwinds as the athleisure trend ebbs." Despite the risks, the analyst points to the company's "strong management team and powerful brand equity" in justifying his neutral stance.
09/26/18
09/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIAB) upgraded to Buy from Neutral at B. Riley FBR. 2. GoPro (GPRO) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying he believes the company has done everything it can to position itself for success. 3. STMicroelectronics (STM) upgraded to Buy from Hold at Deutsche Bank with analyst Johannes Schaller saying the stock has "suffered too much," setting up for an attractive risk/reward profile at current levels. 4. IBM (IBM) upgraded to Buy from Neutral at UBS with analyst John Roy saying the market is pricing in a 2% revenue decline, which IBM can beat. 5. Cheniere Energy (LNG) upgraded to Overweight from Equal Weight at Morgan Stanley and to Outperform from Market Perform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/18
RILY
07/30/18
NO CHANGE
Target $6.3
RILY
Buy
Groupon has ample liquidity to cover IBM award, says B. Riley FBR
B. Riley FBR analyst Sameet Sinha says Groupon (GRPN) has ample liquidity to cover the $83.5M patent award to IBM (IBM). The company has $93M in net cash and an untapped $250M revolver, Sinha tells investors in a research note. He keeps a Buy rating on Groupon shares with a $6.30 price target.
TRUP Trupanion
$35.73

0.81 (2.32%)

08/03/18
COWN
08/03/18
NO CHANGE
Target $47
COWN
Outperform
Trupanion price target raised to $47 from $41 at Cowen
Cowen analyst Thomas Champion raised his price target on Trupanion to $47 from $41 following positive Q2 results. The analyst said pet additions were strong, suggesting ramping growth initiatives and rising efficiency. Champion reiterated his Outperform rating on Trupanion shares.
08/03/18
LSCM
08/03/18
NO CHANGE
Target $46
LSCM
Buy
Trupanion price target raised to $46 from $41 at Lake Street
Lake Street analyst Mark Argento raised his price target for Trupanion to $46 saying the company's "solid" quarter shows it continues to execute. Trupanion is growing its enrolled pets with attractive economics while leveraging its technology platform to enable more Trupanion Express direct pay hospital partner, Argento tells investors in a post-earnings research note. The analyst continues to believe Trupanion's value proposition to both the consumer and the veterinarian remains strong. He reiterates a Buy rating on the shares.
09/06/18
RAJA
09/06/18
INITIATION
Target $46
RAJA
Outperform
Trupanion initiated with an Outperform at Raymond James
Raymond James initiated Trupanion with an Outperform and $46 price target.
08/03/18
RBCM
08/03/18
NO CHANGE
Target $44
RBCM
Outperform
Trupanion price target raised to $44 from $36 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Trupanion to $44 and kept his Outperform rating after its "very strong" Q2 results. The analyst points to the company's accelerating subscription pet growth and expanding EBITDA margins reflecting the company's "very solid" fundamentals.

TODAY'S FREE FLY STORIES

03:00
11/21/18
11/21
03:00
11/21/18
03:00
General news
FX Action: USD-CAD has steadied »

FX Action: USD-CAD has…

02:35
11/21/18
11/21
02:35
11/21/18
02:35
General news
FX Update: The Dollar majors have traded mixed »

FX Update: The Dollar…

02:00
11/21/18
11/21
02:00
11/21/18
02:00
General news
FX Action: USD-JPY has traded moderately firmer »

FX Action: USD-JPY has…

01:45
11/21/18
11/21
01:45
11/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

MDT

Medtronic

$92.31

1.91 (2.11%)

20:48
11/20/18
11/20
20:48
11/20/18
20:48
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic in the midst of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

RDY

Dr. Reddy's

$36.48

1.19 (3.37%)

20:44
11/20/18
11/20
20:44
11/20/18
20:44
Hot Stocks
Dr. Reddy's announces favorable outcome in Buprenorphine and Naloxone litigation »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$35.63

-1.615 (-4.34%)

20:30
11/20/18
11/20
20:30
11/20/18
20:30
Upgrade
Southern Copper rating change at Bradesco »

Southern Copper upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$19.84

0.37 (1.90%)

20:17
11/20/18
11/20
20:17
11/20/18
20:17
Hot Stocks
KB Home expands into Seattle housing market »

KB Home announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$10.69

-0.545 (-4.85%)

20:16
11/20/18
11/20
20:16
11/20/18
20:16
Hot Stocks
Cloudera partners with Bank Rakyat Indonesia »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

AAPL

Apple

$177.10

-8.7 (-4.68%)

19:44
11/20/18
11/20
19:44
11/20/18
19:44
Periodicals
Apple acquires AI software firm Silk Labs, The Information reports »

Apple is said to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

NVT

nVent Electric

$24.18

-0.35 (-1.43%)

19:20
11/20/18
11/20
19:20
11/20/18
19:20
Initiation
nVent Electric initiated at Vertical Research »

nVent Electric initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

FB

Facebook

$132.47

0.85 (0.65%)

19:13
11/20/18
11/20
19:13
11/20/18
19:13
Periodicals
Russia's FAN sues Facebook, claims to be legitimate news outlet, Reuters says »

Facebook is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

, CMCSK

Comcast

$0.00

(0.00%)

18:58
11/20/18
11/20
18:58
11/20/18
18:58
Periodicals
Megyn Kelly seen to leave NBC News with entirety of $69M deal, WSJ says »

Megyn Kelly is…

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, ADSK

Autodesk

$122.99

-2.76 (-2.19%)

18:56
11/20/18
11/20
18:56
11/20/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Foot…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

ADSK

Autodesk

$122.99

-2.76 (-2.19%)

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

KEYS

Keysight Technologies

$54.35

-1.23 (-2.21%)

CPRT

Copart

$47.30

-1.255 (-2.58%)

VNET

21Vianet

$11.20

-0.1 (-0.88%)

GPS

Gap

$24.65

-0.79 (-3.11%)

BILI

Bilibili

$13.61

0.575 (4.41%)

DXCM

DexCom

$119.89

-1.34 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

  • 27

    Nov

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 03

    Mar

AAPL

Apple

$177.10

-8.7 (-4.68%)

18:46
11/20/18
11/20
18:46
11/20/18
18:46
Periodicals
Apple in discussions to give vets access to electronic medical records, WSJ says »

Apple is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

FB

Facebook

$132.47

0.85 (0.65%)

18:32
11/20/18
11/20
18:32
11/20/18
18:32
Periodicals
Facebook ads system was down today for some users, Bloomberg says »

Facebook's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EMCI

EMC Insurance

$32.33

1.1 (3.52%)

18:28
11/20/18
11/20
18:28
11/20/18
18:28
Hot Stocks
EMC Insurance announces receipt of proposal from EMCC to buy all of its shares »

EMC Insurance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$11.09

0.17 (1.56%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Hot Stocks
Emerald Expositions Events announces $20M share repurchase program »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Recommendations
LivaNova analyst commentary at Piper Jaffray »

LivaNova price decline on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

BKH

Black Hills

$64.40

0.92 (1.45%)

18:24
11/20/18
11/20
18:24
11/20/18
18:24
Hot Stocks
Black Hills Energy receives approval to construct $54M gas pipeline in Wyoming »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,026.00

7 (0.69%)

, GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

18:19
11/20/18
11/20
18:19
11/20/18
18:19
Periodicals
Google expands Moffett Park presence again, SVBJ says »

Google is once again…

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

SE

Sea Limited

$12.18

-0.52 (-4.09%)

18:04
11/20/18
11/20
18:04
11/20/18
18:04
Earnings
Sea Limited reports Q3 net loss ($237.6M) vs. ($127.1M) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.61

0.575 (4.41%)

18:03
11/20/18
11/20
18:03
11/20/18
18:03
Earnings
Bilibili reports Q3 revenue $157.1M, consensus $146.72M »

Reports Q3 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LTM

Latam Airlines

$9.24

-0.4 (-4.15%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Breaking Hot Stocks news story on Latam Airlines »

LATAM Airlines reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CE

Celanese

$100.26

-1.53 (-1.50%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Celanese increases Fortron polyphenylene sulphide price by 85c per kg »

The price increases will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.